FDA says Scope Health sold unapproved OTC eye drugs online and misbranded several products.
What happened
On August 28, 2024, FDA reviewed Scope Health's product labeling, including optase.com, where the ophthalmic drug products are available for purchase in the United States without a prescription. FDA found the products are unapproved new drugs and that several are misbranded, including a missing required warning on Dry Eye Intense Drops (multi-use bottle). FDA also says some ingredients are not permitted for OTC ophthalmic demulcent or emollient products under monograph M018.
What FDA found
The eye products are unapproved new drugs because FDA says they are not generally recognized as safe and effective and have no FDA-approved applications.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)MGD Advanced Dry Eye Drops, Dry Eye Intense Drops, and Allegro Eye Drops contain ingredients FDA does not allow as active ingredients in OTC ophthalmic demulcent products under monograph M018.12.
OTC Monograph M018.12; FD&C Act section 505GHYLO Night Eye Ointment contains vitamin A, which FDA does not allow as an active ingredient in OTC ophthalmic emollient products under M018.14.
OTC Monograph M018.14; FD&C Act section 505GDry Eye Intense Drops (multi-use bottle) lacks the required warning “If solution changes color or becomes cloudy, do not use.”
FD&C Act section 502(f)(2), 21 U.S.C. 352(f)(2); M018.60Allegro Eye Drops, MGD Advanced Dry Eye Drops, Dry Eye Intense Drops (multi-use and single dose), and HYLO Night Eye Ointment are misbranded because they do not meet section 505G requirements and are not FDA-approved.
FD&C Act section 502(ee), 21 U.S.C. 352(ee)
What FDA wants
FDA asks Scope Health to investigate and correct the violations, prevent recurrence, and respond in writing within 15 working days with steps taken, documentation, or reasoning if it disagrees. Send the response to FDAAdvisory@fda.hhs.gov with the firm name and identifier 695085.
Who should pay attention
- retailers and online marketplaces selling eye-care products
- brands that distribute OTC ophthalmic products
- consumers using dry eye or blepharitis products
This is a summary. Read the original letter on fda.gov.